Takeda's Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years

Experts Reviewed Data from QDENGA’s Clinical Program Across 19 Phase 1, 2 and 3 Trials with More Than 28,000 ParticipantsWHO Will Consider the SAGE Recommendation and Provide Final Guidance on the Use of QDENGA in Public Vaccination Programs in the Coming MonthsDengue Poses a Significant and Growing Public Health Bu...

Related Keywords

Sri Lanka ,United States ,Colombia ,Philippines ,Osaka ,Japan ,Nicaragua ,Dominican Republic ,Argentina ,Indonesia ,Thailand ,Brazil ,Panama ,Japanese ,America ,Maiko Miura ,Gary Dubin ,Strategic Advisory Group Of Experts ,Exchange Commission ,Clinical Program ,Takeda Pharmaceutical Company Limited ,World Health Organization ,European Union Eu Member States ,Public Health Burden To People Living ,Data Monitoring Committee ,Experts Reviewed Data ,Program Across ,More Than ,Provide Final Guidance ,Public Vaccination Programs ,Growing Public Health Burden ,People Living ,Strategic Advisory Group ,Dengue Tetravalent Vaccine ,Latin America ,Global Vaccine Business Unit ,Dengue Efficacy Study ,European Union ,Member States ,Product Characteristics ,Annual Report ,Published March ,Tetravalent Dengue Vaccine Candidate ,Northern European Conference ,Travel Medicine ,Retrieved October ,Tetravalent Dengue Vaccine ,Healthy Children ,Retrieved July ,Health Organization ,Technical Report Series ,What You Need ,Published April ,